Liaoning Chengda Biotechnology Co Ltd
SSE:688739

Watchlist Manager
Liaoning Chengda Biotechnology Co Ltd Logo
Liaoning Chengda Biotechnology Co Ltd
SSE:688739
Watchlist
Price: 27.7 CNY -3.65% Market Closed
Market Cap: 5.1B CNY
Have any thoughts about
Liaoning Chengda Biotechnology Co Ltd?
Write Note

Liaoning Chengda Biotechnology Co Ltd
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Liaoning Chengda Biotechnology Co Ltd
Total Current Liabilities Peer Comparison

Comparables:
6160
603392
002252
300122
300896

Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Liaoning Chengda Biotechnology Co Ltd
SSE:688739
Total Current Liabilities
ÂĄ356.8m
CAGR 3-Years
16%
CAGR 5-Years
30%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Current Liabilities
ÂĄ12.8B
CAGR 3-Years
22%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Current Liabilities
ÂĄ2.7B
CAGR 3-Years
48%
CAGR 5-Years
51%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Total Current Liabilities
ÂĄ1.6B
CAGR 3-Years
27%
CAGR 5-Years
41%
CAGR 10-Years
32%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Current Liabilities
ÂĄ22.7B
CAGR 3-Years
32%
CAGR 5-Years
39%
CAGR 10-Years
68%
Imeik Technology Development Co Ltd
SZSE:300896
Total Current Liabilities
ÂĄ297.7m
CAGR 3-Years
49%
CAGR 5-Years
46%
CAGR 10-Years
N/A

See Also

What is Liaoning Chengda Biotechnology Co Ltd's Total Current Liabilities?
Total Current Liabilities
356.8m CNY

Based on the financial report for Dec 31, 2023, Liaoning Chengda Biotechnology Co Ltd's Total Current Liabilities amounts to 356.8m CNY.

What is Liaoning Chengda Biotechnology Co Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
30%

Over the last year, the Total Current Liabilities growth was 31%. The average annual Total Current Liabilities growth rates for Liaoning Chengda Biotechnology Co Ltd have been 16% over the past three years , 30% over the past five years .

Back to Top